Skip to main content
Top
Published in: Neurocritical Care 2/2020

01-10-2020 | Stroke | Brief Communication

Resource Allocation: Stable Patients Remain Stable 12–24 h Post-tPA

Authors: Sheena Khan, Alexandria Soto, Elisabeth B. Marsh

Published in: Neurocritical Care | Issue 2/2020

Login to get access

Abstract

Background and Purpose

Stroke patients are currently monitored for neurological deterioration for 24 h following treatment with intravenous tissue plasminogen activator (IV tPA) or mechanical thrombectomy. This requires low nursing ratios and an intensive-care-like setting. As the half-life of IV tPA is short, many patients may not require such prolonged intensive monitoring and could be downgraded much earlier. We evaluate the frequency of neurological deterioration in the 0–12 and 12–24 h post-treatment windows.

Methods

Patients presenting with acute ischemic stroke treated with IV tPA and/or thrombectomy at our institution from 2016–2018 were prospectively followed per protocol for 24 h post-therapy (examinations every 15 min for 2 h, every 30 min for 6 h, and hourly thereafter). Neurological deteriorations were recorded along with interventions and complications. Frequency of deterioration within the 0–12 and 12–24 h post-treatment windows was determined, along with factors associated with decline at each time point.

Results

A total of 172 patients were treated (IV:135, IA:65, both:30). Thirty-six (21%) experienced a documented neurologic deterioration [8 due to intracerebral hemorrhage (4.7%)]. Five patients deteriorated in the 12–24 h window; all but one had experienced earlier examination changes. Elevated NIHSS was associated with a higher likelihood of deterioration overall. Early fluctuation was associated with decline after 12 h.

Conclusions

New onset of neurologic deterioration is rare 12–24 h after treatment of acute stroke. Stable patients with low NIHSS scores and no ICU needs may not require intensive monitoring greater than 12 h post-treatment.
Literature
1.
go back to reference National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–8.CrossRef National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–8.CrossRef
2.
go back to reference Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, ESCAPE Trial Investigators, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. NEJM. 2015;372:1019–30.CrossRef Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, ESCAPE Trial Investigators, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. NEJM. 2015;372:1019–30.CrossRef
3.
go back to reference Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the Am Stroke Association. Stroke. 2003;34:1056–83.CrossRef Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the Am Stroke Association. Stroke. 2003;34:1056–83.CrossRef
4.
go back to reference Faigle R, Sharrief A, Marsh EB, Llinas RH, Urrutia VC. Predictors of critical care needs after IV thrombolysis for acute ischemic stroke. PLoS ONE. 2014;9(2):e88652.CrossRef Faigle R, Sharrief A, Marsh EB, Llinas RH, Urrutia VC. Predictors of critical care needs after IV thrombolysis for acute ischemic stroke. PLoS ONE. 2014;9(2):e88652.CrossRef
5.
go back to reference Chang A, Llinas EJ, Chen K, Llinas RH, Marsh EB. Shorter intensive care unit stays? The majority of post-intravenous tpa (tissue-type plasminogen activator) symptomatic hemorrhages occur within 12 h of treatment. Stroke. 2018;49(6):1521–4.CrossRef Chang A, Llinas EJ, Chen K, Llinas RH, Marsh EB. Shorter intensive care unit stays? The majority of post-intravenous tpa (tissue-type plasminogen activator) symptomatic hemorrhages occur within 12 h of treatment. Stroke. 2018;49(6):1521–4.CrossRef
6.
go back to reference Kasner SE, Chalela JA, Luciano JM, et al. Reliability and validity of estimating the NIHS stroke scale score from medical records. Stroke. 1999;30(8):1534–7.CrossRef Kasner SE, Chalela JA, Luciano JM, et al. Reliability and validity of estimating the NIHS stroke scale score from medical records. Stroke. 1999;30(8):1534–7.CrossRef
7.
go back to reference Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283(9):1145–50.CrossRef Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283(9):1145–50.CrossRef
Metadata
Title
Resource Allocation: Stable Patients Remain Stable 12–24 h Post-tPA
Authors
Sheena Khan
Alexandria Soto
Elisabeth B. Marsh
Publication date
01-10-2020
Publisher
Springer US
Published in
Neurocritical Care / Issue 2/2020
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-019-00889-z

Other articles of this Issue 2/2020

Neurocritical Care 2/2020 Go to the issue

Response to Letter To The Editor

Response to Drs. Quintard, et al.